Target and disease logic
Prioritize diseases, targets, and mechanisms where Bangladesh can build a meaningful research foothold.
Preclinical drug discovery
Starting a discovery culture where none has yet taken root.
Bangladesh has strong pharma manufacturing capacity, but original small-molecule discovery remains largely absent. Chem2Cure aims to build the scientific habits, teams, and workflows needed to change that trajectory.
First principles
Discovery is not one tool or one assay. It is a disciplined loop between chemistry, biology, computation, pharmacology, safety, and decision making.
Discovery operating model
A practical preclinical pipeline for Bangladesh.
Hit finding
Use literature, patents, virtual screening, fragment thinking, and existing chemical matter to identify starting points.
Synthesis and SAR
Design analogs, build focused libraries, interpret activity, and connect molecular changes to biological response.
ADME and safety
Introduce solubility, permeability, stability, selectivity, and early safety thinking before expensive failure.
Preclinical readiness
Prepare the evidence package needed for partnerships, grants, and translational next steps.
AI-aided discovery workflow
Input: target structure, known ligands, disease context
Model: structure prediction, docking, affinity ranking, property filters
Chemist review: synthetic feasibility, novelty, SAR hypothesis
Output: prioritized molecules for purchase, synthesis, or collaboration
AI readiness
AI should help chemists think better, not replace scientific judgment.
Chem2Cure introduces AI as an integrated research workflow: structure prediction, docking, library triage, property prediction, and literature intelligence. Every output still needs human medicinal chemistry judgment.
- Target and protein-structure preparation
- Virtual screening and prioritization
- Chemist-reviewed shortlist generation
- Cost-aware experimental planning
Research themes
Areas where Bangladesh can build capability.
Neglected and infectious diseases
Dengue, emerging viral threats, and regionally relevant diseases where local need is high.
Rare and genetic diseases
Capacity building around diagnosis, therapy discovery, and patient-centered translational research.
Fine and specialty chemicals
Skill transfer toward fragrances, food chemicals, agrochemicals, and higher-value chemical industries.
CRO and CDMO readiness
Training chemists for contract research, analytical documentation, and global partnership standards.